February 2007
Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p3
Trade Publication
The article reports that Oncolytics Biotech Inc., a Calgary, Alberta-based biotechnology company, has received a letter of approval from Great Britain's Medicines and Healthcare Products Regulatory Agency for its application for a clinical trial using intravenous administration of Reolysin in patients with advanced cancers. The principal investigators are Kevin Harrington of The Institute of Cancer Research and Geoff Hall of St. James's Hospital.


Related Articles

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;7/26/2008, Issue 1212, p2 

    This section offers news briefs on issues related to pharmacovigilance. Neurogen Corp. has suspended a clinical trial investigating the treatment of insomnia with a bilayer tablet formulation of adipiplon due to a higher rate of unwanted next day effects. The Canadian government is planning to...

  • High-dose simvastatin myopathy risk. Robinson, Stephen // GP: General Practitioner;5/21/2010, p16 

    The article reports on a warning by the Medicines and Healthcare Products Regulatory Agency (MHRA) regarding the use of 80mg simvastatin only in severe cases. According to the agency, patients currently taking simvastatin 80mg should continue taking their medicine. It is stated that the decision...

  • Agency is criticised after granting a licence for a homeopathic remedy. Cohen, Deborah // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/23/2009, Vol. 338 Issue 7705, p1230 

    The article reports the Medicines and Healthcare Products Regulatory Agency (MHRA) has been given permission to add homeopathic remedies to its list of prescribed medications. The decision has raised concerns since such traditional medicines have not passed scientific or research standards for...

  • Use of herbal medicines. Newson, Louise // GP: General Practitioner;3/16/2007, p46 

    The article reports on the status of herbal medicine in Great Britain. Legally, herbal products are classified as food supplements and are widely available from health food shops and chemists. For most herbal treatments trials of efficacy are lacking. In Great Britain, the Medicines and...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;11/28/2009, Issue 1280, p2 

    This section offers news briefs related to the pharmaceutical industry. A safety review is being undertaken by the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) on sibutramine-containing medicines. A campaign was launched by the British Medicines and...

  • Oncolytics Biotech completes dose escalation in Reolysin-docetaxel trial.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p16 

    The article reports on the result of the study conducted by Oncolytics Biotech Inc. which assesses the effectiveness of Reolysin drug, along with docetaxel, in the treatment of cancer. The study involved a non-randomized trial by focusing on the ability of the drug to treat the disease through...

  • GW Pharma Enters Home Stretch for Launch of MS Drug Sativex. Moran, Nuala // BioWorld International;3/24/2010, Vol. 15 Issue 12, p1 

    The article announces the approval for the cannabis-based medicine Sativex by the U.S. and Europe. It is expected to be approved for treating spasticity in multiple sclerosis as well as cancer pain after positive results in a Phase IIb U.S. trial of the medicine were presented. The Medicines and...

  • Cheap AMD treatment blocked by drug company.  // PharmacoEconomics & Outcomes News;Apr2015, Vol. 726 Issue 1, p3 

    Te article offers information the move of pharmaceutical firm Novartis to block the use of Avastin to treat age-related macular degeneration (AMD) in Great Britain. Topics include the expensive AMD treatment called ranibizumab marketed by Novartis, the cost effectiveness of Avastin, and the use...

  • News in brief.  // Nature Reviews Drug Discovery;Jan2007, Vol. 6 Issue 1, p14 

    The article offers news briefs on public health care. Pfizer Inc., a research-based pharmaceuticals firm has stopped trials of torcetrapib, a drug for cardiovascular disease, after some patients had died. Andrew von Eschenbach, has been confirmed as Commissioner of Foods and Drugs Administration...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics